Based on the key indicators related to Kalvista Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Kalvista Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Kalvista Pharmaceuticals' Common Stock Shares Outstanding is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to climb to about 284.3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.1 M in 2025. Key indicators impacting Kalvista Pharmaceuticals' financial strength include:
The financial analysis of Kalvista Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Kalvista Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Kalvista Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kalvista Pharmaceuticals. Check Kalvista Pharmaceuticals' Beneish M Score to see the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.
Kalvista Pharmaceuticals Stock Summary
Kalvista Pharmaceuticals competes with Crinetics Pharmaceuticals, Kura Oncology, Viridian Therapeutics, Replimune, and Nuvectis Pharma. KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. Kalvista Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Kalvista Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Kalvista Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Kalvista Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kalvista Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kalvista Pharmaceuticals competition to find correlations between indicators driving Kalvista Pharmaceuticals's intrinsic value. More Info.
Kalvista Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Kalvista Pharmaceuticals' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Kalvista Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Kalvista Pharmaceuticals Systematic Risk
Kalvista Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kalvista Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Kalvista Pharmaceuticals correlated with the market. If Beta is less than 0 Kalvista Pharmaceuticals generally moves in the opposite direction as compared to the market. If Kalvista Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kalvista Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kalvista Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Kalvista Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Kalvista Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kalvista Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Kalvista Pharmaceuticals growth as a starting point in their analysis.
Kalvista Pharmaceuticals March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kalvista Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kalvista Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kalvista Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Kalvista Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kalvista Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.